[MTOR inhibitors: from transplantation to oncology. AFU 2006 Transplantation Committee Review of the literature].
The use of mTOR inhibitors started about 30 years ago following the discovery of rapamycin, a macrolide derived from a soilborne microorganism Streptomyces hygroscopicus that exerts antibiotic, immunosuppressive and antiproliferative properties. Initially intended to be used as an antibiotic, a more detailed understanding of the mechanism of action of this class of drugs has rationalized and validated its use in the field of transplantation and oncology. Many clinical trials on mTOR inhibitors have been conducted in these two fields, in which urologists are actively involved. This review summarizes the current knowledge on the mechanism of action and clinical applications of mTOR inhibitors in renal transplantation and oncology.
Neuzillet
Yann
Y
Service d'Urologie et Transplantation Rénale, CHU de la Conception, Marseille, France.
Karam
Georges
G
Lechevallier
Eric
E
Kleinclauss
François
F
D001379:Azathioprine / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D016030:Kidney Transplantation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011494:Protein Kinases / Q000378:metabolism*; D058570:TOR Serine-Threonine Kinases
D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D001379:Azathioprine